Tuberculosis control in South African gold mines: Mathematical modeling of a trial of community-wide isoniazid preventive therapy

American Journal of Epidemiology

Volumn 181, Issue 8, 2015, Pages 619-632

  Vynnycky, Emilia ^a,b   Sumner, Tom ^b   Fielding, Katherine L ^b   Lewis, James J ^b   Cox, Andrew P ^b   Hayes, Richard J ^b   Corbett, Elizabeth L ^b,c   Churchyard, Gavin J ^b,d,e   Grant, Alison D ^b   White, Richard G ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c MALAWI LIVERPOOL WELLCOME TRUST CLINICAL RESEARCH PROGRAMME   (Malawi)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e AURUM INSTITUTE   (South Africa)

Author keywords

mass community wide isoniazid preventive therapy; mathematical model; tuberculosis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ISONIAZID; RIFAPENTINE; GOLD; TUBERCULOSTATIC AGENT;

DATA SET; DISEASE CONTROL; DISEASE PREVALENCE; DISEASE TREATMENT; GOLD MINE; MATHEMATICAL ANALYSIS; NUMERICAL MODEL; TUBERCULOSIS; VIRAL DISEASE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INFECTION; INFECTION RISK; MASS SCREENING; MATHEMATICAL MODEL; MINER; MINING; MORTALITY; MYCOBACTERIUM TUBERCULOSIS TEST KIT; OUTCOME ASSESSMENT; POPULATION; PREVALENCE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SCALE UP; SOUTH AFRICA; THERAPY DELAY; TUBERCULOSIS; TUBERCULOSIS CONTROL; COMPLICATION; MIDDLE AGED; PUBLIC HEALTH SERVICE; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL;

SOUTH AFRICA;

HUMAN IMMUNODEFICIENCY VIRUS;

ADULT; ANTITUBERCULAR AGENTS; GOLD; HIV INFECTIONS; HUMANS; ISONIAZID; MIDDLE AGED; MINING; MODELS, THEORETICAL; PUBLIC HEALTH PRACTICE; SOUTH AFRICA; TUBERCULOSIS;

EID: 84918783346     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwu320     Document Type: Article

References (48)

1. World Health Organization. Global Tuberculosis Report, 2012. Geneva, Switzerland: World Health Organization; 2012.
2. van Halsema CL, Fielding KL, Chihota VN, et al. Trends in drugresistant tuberculosis in a gold-mining workforce in SouthAfrica, 2002-2008. Int J Tuberc Lung Dis. 2012;16(7):967-973.
3. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970;26:28-106.
4. Fielding KL, Grant AD, Hayes RJ, et al. Thibela TB: design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis amongst gold miners in South Africa. Contemp Clin Trials. 2011;32(3):382-392.
5. Churchyard GJ, Fielding KL, Lewis JJ, et al. A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med. 2014;370(4):301-310.
6. Esmail H, Barry CE 3rd, Wilkinson RJ. Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug Discov Today. 2012;17(9-10):514-521.
7. Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect. 1997;119(2):183-201.
8. Dye C, Garnett GP, Sleeman K, et al. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet. 1998;352(9144): 1886-1891.
9. Godfrey-Faussett P, Sonnenberg P, Shearer SC, et al. Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet. 2000;356(9235):1066-1071.
10. Corbett EL, Mallory KF, Grant AD, et al. HIV-1 infection and risk of tuberculosis after rifampicin treatment. Lancet. 2001; 357(9260):957-958.
11. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel isoniazid studies. Am Rev Respir Dis. 1979;119(5): 827-830.
12. Quigley MA, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS. 2001;15(2):215-222.
13. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011; 377(9777):1588-1598.
14. ComstockGW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999;3(10):847-850.
15. Hallett TB, Gregson S, Mugurungi O, et al. Assessing evidence for behaviour change affecting the course of HIV epidemics: a new mathematical modelling approach and application to data from Zimbabwe. Epidemics. 2009;1(2):108-117.
16. Alkema L, Raftery AE, Clark SJ. Probabilistic projections of HIV prevalence using Bayesian melding. Ann Appl Stat. 2007; 1(1):229-248.
17. Brown T, Salomon JA, Alkema L, et al. Progress and challenges in modelling country-level HIV/AIDS epidemics: the UNAIDS Estimation and Projection Package 2007. Sex Transm Infect. 2008;84(suppl 1):i5-i10.
18. Alkema L, Raftery AE, Brown T. Bayesian melding for estimating uncertainty in national HIV prevalence estimates. Sex Transm Infect. 2008;84(suppl 1):i11-i16.
19. Orroth KK, White RG, Korenromp EL, et al. Empirical observations underestimate the proportion of human immunodeficiency virus infections attributable to sexually transmitted diseases in the Mwanza and Rakai sexually transmitted disease treatment trials: simulation results. Sex Transm Dis. 2006;33(9):536-544.
20. Chaisson RE, Clermont HC, Holt EA, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med. 1996;154(4 Pt 1):1034-1038.
21. Halsey NA, Coberly JS, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet. 1998;351(9105): 786-792.
22. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS. 2001;15(16):2137-2147.
23. Cowie RL. Short course chemoprophylaxis with rifampicin, isoniazid and pyrazinamide for tuberculosis evaluated in gold miners with chronic silicosis: a double-blind placebo controlled trial. Tuber Lung Dis. 1996;77(3):239-243.
24. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis. 1992;145(1):36-41.
25. Rimal B, Greenberg AK, Rom WN. Basic pathogenetic mechanisms in silicosis: current understanding. Curr Opin Pulm Med. 2005;11(2):169-173.
26. Department of Health. The South African Antiretroviral Treatment Guidelines. Pretoria, South Africa: Department of Health; 2013.
27. Hnizdo E, Murray J, Sluis-Cremer GK, et al. Correlation between radiological and pathological diagnosis of silicosis: an autopsy population based study. Am J Ind Med. 1993;24(4): 427-445.
28. Murray J, Sonnenberg P, Nelson G, et al. Cause of death and presence of respiratory disease at autopsy in an HIV-1 seroconversion cohort of southern African gold miners. AIDS. 2007;21(suppl 6):S97-S104.
29. Corbett EL, Murray J, Churchyard GJ, et al. Use of miniradiographs to detect silicosis. Comparison of radiological with autopsy findings. Am J Respir Crit Care Med. 1999; 160(6):2012-2017.
30. Lin HH, Dowdy D, Dye C, et al. The impact of new tuberculosis diagnostics on transmission: why context matters. Bull World Health Organ. 2012;90(10):739-747A.
31. Wood R, Liang H, Wu H, et al. Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa. Int J Tuberc Lung Dis. 2010;14(4): 406-412.
32. Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet. 1999;353(9151):444-449.
33. Sutherland I, Svandová E, Radhakrishna S. The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands. Tubercle. 1982;63(4):255-268.
34. Clark M, Vynnycky E. The use of maximum likelihood methods to estimate the risk of tuberculous infection and disease in a Canadian First Nations population. Int J Epidemiol. 2004;33(3):477-484.
35. Vynnycky E, Borgdorff MW, Leung CC, et al. Limited impact of tuberculosis control in Hong Kong: attributable to high risks of reactivation disease. Epidemiol Infect. 2008;136(7): 943-952.
36. Corbett EL, Churchyard GJ, Clayton TC, et al. HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. AIDS. 2000;14(17):2759-2768.
37. Corbett EL, Charalambous S, Moloi VM, et al. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med. 2004;170(6):673-679.
38. Lewis JJ, Charalambous S, Day JH, et al. HIV infection does not affect active case finding of tuberculosis in South African gold miners. Am J Respir Crit Care Med. 2009;180(12): 1271-1278.
39. Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9(7): e1001270.
40. Williams BG, Granich R, De Cock KM, et al. Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci U S A. 2010;107(45):19485-19489.
41. Williams BG, Korenromp EL, Gouws E, et al. HIV infection, antiretroviral therapy, and CD4+ cell count distributions in African populations. J Infect Dis. 2006;194(10):1450-1458.
42. Rangaka MX, Boulle A, Wilkinson RJ, et al. Randomized controlled trial of isoniazid preventive therapy in HIV-infected persons on antiretroviral therapy. Presented at the XIX International AIDS Conference, Washington, DC, July 22-27, 2012.
43. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23(5): 631-636.
44. Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;21(11):1441-1448.
45. TiemersmaEW, van derWerf MJ, BorgdorffMW, et al. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One. 2011;6(4):e17601.
46. Churchyard GJ, Kleinschmidt I, Corbett EL, et al. Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2000;4(8):705-712.
47. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155-2166.
48. Dorman SE, Chihota VN, Lewis JJ, et al. Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis prevalence survey. PLoS One. 2012;7(8):e43307.